Meta-analysis of pooled outcome measures
| Studies | Participants | RR (95% CI) | |
| Primary outcomes | |||
| BPD 36 weeks PMA | 3 | 418 | 0.81 (0.63 to 1.04) |
| Combined BPD and mortality 36 weeks PMA | 3 | 435 | 0.89 (0.65 to 1.21) |
| Death before discharge | 3 | 435 | 0.92 (0.51 to 1.65) |
| Secondary outcomes | |||
| Failure to extubate | 4 | 463 | 0.51 (0.37 to 0.70) |
| Tachycardia | 5 | 528 | 3.39 (1.50 to 7.64) |
| NEC ≥ grade 2 | 4 | 530 | 0.82 (0.36 to 1.90) |
| SIP | 1 | 74 | 1.00 (0.22 to 4.64) |
| IVH > grade 2 | 4 | 567 | 1.24 (0.65 to 2.36) |
| Hyperglycemia | 2 | 47 | 1.92 (0.47 to 7.94) |
| ROP≥ grade 3 | 3 | 390 | 0.60 (0.28 to 1.29) |
| Long term outcomes | |||
| Mortality < 12 months CA | 2 | 304 | 0.93 (0.47 to 1.85) |
| Major disability at 12 months CA | 1 | 190 | 0.58 (0.26 to 1.25) |
| Death or disability at 12 months CA | 2 | 207 | 1.19 (0.37 to 3.77) |
| GQ at 12 months CA | 1 | 190 | 4.40 (0.07 to 8.73) |
Hyperglycaemia as defined by the original authors. Major disability defined as defined as having cerebral palsy, general quotient<75, bilateral blindness and/or deafness at 12 months corrected age.
RR, relative risk.